news Open source all-atom model of entire COVID-19 S protein released 23 June 2020 | By Victoria Rees (Drug Target Review) Researchers have developed a video and model-building programme for other scientists to build full-length COVID-19 S protein models.
news Potential target to control T follicular helper cells identified 23 June 2020 | By Victoria Rees (Drug Target Review) A new study shows how the Bcl6 protein can regulate T follicular helper cells, presenting a target for autoimmune and infectious diseases.
news N terminal domain of S protein revealed as antibody target for COVID-19 23 June 2020 | By Victoria Rees (Drug Target Review) An antibody with high neutralising potency against SARS-CoV-2 that binds to the N terminal domain of the Spike protein has been identified by a team researching COVID-19 therapeutics.
news MMR vaccine could protect against COVID-19 sepsis, paper says 22 June 2020 | By Victoria Rees (Drug Target Review) Researchers have suggested that the MMR live attenuated vaccine could be used to provide non-specific protection to patients against sepsis associated with COVID-19.
news Silicon-based agent could prevent progression of kidney disease and Parkinson’s 19 June 2020 | By Victoria Rees (Drug Target Review) Japanese researchers have shown that a silicon-based antioxidant agent can suppress the development of kidney failure and Parkinson's disease in rodent models.
news Screening reveals nelfinavir and amodiaquine combat COVID-19 in cell cultures 18 June 2020 | By Victoria Rees (Drug Target Review) Researchers who screened 136 broad-spectrum antivirals identified six with the most activity against COVID-19 and an optimum combination of two to fight the virus.
news Potential for Mycoplasma pneumoniae vaccine through lipoprotein removal, finds study 18 June 2020 | By Victoria Rees (Drug Target Review) A new study has shown that effective and safe M. pneumoniae vaccine could be possible by removing certain lipoproteins from the bacteria.
news Two small molecules revealed to combat mouse tumour growth in multiple cancers 17 June 2020 | By Victoria Rees (Drug Target Review) Small molecules named CS1 (bisantrene) and CS2 (brequinar) have been developed by researchers to suppress the growth of tumours and have shown promise in mouse models.
news New genetically attenuated parasite gives hope for malaria vaccine 17 June 2020 | By Victoria Rees (Drug Target Review) Using a genetically attenuated parasite (GAP) with a particular deleted gene, researchers have developed a new potential malaria vaccine that arrests at the late liver stage.
news “Potent” antibodies provide protection from COVID-19 in cell cultures, finds study 16 June 2020 | By Victoria Rees (Drug Target Review) Newly discovered antibodies found in the blood of recovered COVID-19 patients could provide robust protection against SARS-CoV-2, say researchers.
webinar Improving cell-based assays and their future in drug discovery 15 June 2020 | By Horizon Discovery Watch our on-demand webinar with Horizon Discovery which summarises the challenges in translating promising pre-clinical therapeutic candidates into clinical success.
news Link identified between COVID-19 and onset of diabetes 15 June 2020 | By Victoria Rees (Drug Target Review) New research indicates COVID-19 could trigger the development of diabetes in healthy people, prompting experts to establish a registry for COVID-19 and diabetes data.
news Compound from clams combats many common infections from parasites, finds study 12 June 2020 | By Victoria Rees (Drug Target Review) A compound called tartrolon E, a byproduct of bacteria from shipworms, has been identified as researchers with the potential to fight and kill several parasites, including Cryptosporidium.
news SARS-CoV-2 immunodominant epitopes identified as vaccine candidates 12 June 2020 | By Victoria Rees (Drug Target Review) Researchers have analysed the SARS-CoV-2 proteome to reveal seven promising immunodominant epitopes that could aid in the development of a COVID-19 vaccine.
article What immuno-oncology research can tell us about COVID-19 11 June 2020 | By Dr Jing Watnick (Vigeo Therapeutics) Dr Jing Watnick discusses how lessons learnt from cancer immunotherapy treatments could be applied to the development of COVID-19 therapies.
